Erlotinib and Sunitinib in NSCLC
* To determine the safety and maximally tolerated dose of sunitinib plus erlotinib in patients with non-small cell lung cancer (NSCLC).
* To determine response to sunitinib plus erlotinib in patients with non-small cell lung cancer.
Non Small Cell Lung Cancer
DRUG: erlotinib, sunitinib
Safety, 12 months
Response rate, 12 months
* To determine the safety and maximally tolerated dose of sunitinib plus erlotinib in patients with non-small cell lung cancer (NSCLC).
* To determine response to sunitinib plus erlotinib in patients with non-small cell lung cancer.